Evaluate Vantage Homepage

Vantage logo

Cytokine players keep the faith

The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.

Medtech

Company Events

Interviews